Last reviewed · How we verify
Varilrix
At a glance
| Generic name | Varilrix |
|---|---|
| Also known as | ATC J07BK01 |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Second Dose of Varicella Vaccine in Healthy Children (PHASE3)
- Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
- Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon (PHASE1, PHASE2)
- Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine (PHASE3)
- Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients (PHASE2, PHASE3)
- Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. (PHASE3)
- Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine (PHASE4)
- A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Varilrix CI brief — competitive landscape report
- Varilrix updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI